A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3

This is a noninterventional, observational, long-term follow-up (LTFU) study. Patients in this study will be followed for 5 years from enrollment on this study to assess potential delayed risks of RPx products. Eligible participants for this LTFU study include patients who received at least 1 dose of an RPx product under the interventional parent study. Patients will be rolled over into this LTFU study after completion of the Replimune-sponsored parent study (ie, either completion of the LTFU in the parent study or withdrawal from the parent study). All patients in ongoing RPx studies will be asked to participate in this LTFU study so that the Sponsor can evaluate potential delayed risks.

NCT Number	NCT06887348
Lead Sponsor	Replimune Inc.
Conditions	Melanoma, Metastatic Melanoma, Advanced Solid Tumor, Hepatocellular Carcinoma
Enrollment	50 participants
Start Date	2025-12-12
Primary Completion	2030-12 (estimated)
Study Completion	2035-12 (estimated)
Updated on ClinicalTrials.gov	2026-01-12